KIND Gets FDA Orphan Drug Designation for Sickle Cell Disease Treatment

KINDPharmaceutical, a biotech company, announced that the FDA has granted Orphan Drug Designation to their drug AND017 for treating sickle cell disease. AND017 is being developed by KIND to treat various anemia indications. The ODD for SCD underscores the potential of AND017 to address the significant unmet medical needs of the over 120,000 SCD patients in the U.S. It provides KIND with incentives to help develop AND017 as a potential new oral therapy. “This FDA designation underscores the importance of finding better treatments for sickle cell disease,” said KIND’s CEO Dong Liu.

At OxyDial, we’re encouraged to see innovative companies like KIND working on solutions for underserved patient populations dealing with challenging conditions like SCD. We’re hopeful AND017 can make a real difference in the lives of those affected by this debilitating disease.